Phase II Trial of Elotuzumab with Lenalidomide and Low-Dose Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma


Phase II Trial of Elotuzumab with Lenalidomide and Low-Dose Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma
Slides from a presentation at ASH 2011 and transcribed comments from a recent interview with Sagar Lonial, MD (1/25/12)

Lonial S et al. A Phase 2 study of elotuzumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma. Proc ASH 2011;Abstract 303.

Dr Lonial is Vice Chair of Clinical Affairs and Director of Translational Research at the Emory University School of Medicine’s Winship Cancer Institute in Atlanta, Georgia.